Product
PLX038 + Tuvusertib
1 clinical trial
1 indication
Indication
Solid TumorClinical trial
A Phase I Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) With Dose Expansion Cohorts in Patients With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-06-15